Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans : An open-label preliminary investigation. / Burmester, Daniel Rødbro; Madsen, Martin Korsbak; Szabo, Attila; Aripaka, Sagar Sanjay; Stenbæk, Dea Siggaard; Frokjaer, Vibe G.; Elfving, Betina; Mikkelsen, Jens D.; Knudsen, Gitte Moos; Fisher, Patrick Mac Donald.
I: Comprehensive Psychoneuroendocrinology, Bind 13, 100163, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans
T2 - An open-label preliminary investigation
AU - Burmester, Daniel Rødbro
AU - Madsen, Martin Korsbak
AU - Szabo, Attila
AU - Aripaka, Sagar Sanjay
AU - Stenbæk, Dea Siggaard
AU - Frokjaer, Vibe G.
AU - Elfving, Betina
AU - Mikkelsen, Jens D.
AU - Knudsen, Gitte Moos
AU - Fisher, Patrick Mac Donald
N1 - Publisher Copyright: © 2022 The Authors
PY - 2023
Y1 - 2023
N2 - Rationale: Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous studies indicate a link between neuropsychiatric disorders and inflammatory processes. However, the effect of psilocybin on biomarkers of inflammation has not been evaluated in humans. Objectives: Investigate the effect of a single dose of psilocybin on peripheral biomarkers of inflammation in healthy humans. Methods: Blood samples were collected from 16 healthy participants before and one day after the administration of a single oral dose of psilocybin (mean dose: 0.22 mg/kg) and subsequently analyzed for concentrations of high-sensitivity C-reactive protein (hsCRP), tumor-necrosis-factor (TNF) and soluble urokinase plasminogen activator receptor (suPAR). Change in inflammatory markers was evaluated using a paired t-test where p < 0.05 was considered statistically significant. Results: We did not observe statistically significant changes in any of the above biomarkers of inflammation (all Cohen's d ≤ 0.31; all p ≥ 0.23). Conclusions: Our data do not support that a single dose of psilocybin reduces biomarkers of inflammation in healthy individuals one day after administration. Nevertheless, we suggest that future studies consider additional markers of inflammation, including markers of neuroinflammation, and evaluate potential anti-inflammatory effects of psilocybin therapy in clinical cohorts where more prominent effects may be observable.
AB - Rationale: Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous studies indicate a link between neuropsychiatric disorders and inflammatory processes. However, the effect of psilocybin on biomarkers of inflammation has not been evaluated in humans. Objectives: Investigate the effect of a single dose of psilocybin on peripheral biomarkers of inflammation in healthy humans. Methods: Blood samples were collected from 16 healthy participants before and one day after the administration of a single oral dose of psilocybin (mean dose: 0.22 mg/kg) and subsequently analyzed for concentrations of high-sensitivity C-reactive protein (hsCRP), tumor-necrosis-factor (TNF) and soluble urokinase plasminogen activator receptor (suPAR). Change in inflammatory markers was evaluated using a paired t-test where p < 0.05 was considered statistically significant. Results: We did not observe statistically significant changes in any of the above biomarkers of inflammation (all Cohen's d ≤ 0.31; all p ≥ 0.23). Conclusions: Our data do not support that a single dose of psilocybin reduces biomarkers of inflammation in healthy individuals one day after administration. Nevertheless, we suggest that future studies consider additional markers of inflammation, including markers of neuroinflammation, and evaluate potential anti-inflammatory effects of psilocybin therapy in clinical cohorts where more prominent effects may be observable.
KW - Biomarkers
KW - hsCRP
KW - Immune system
KW - Inflammation
KW - Neuroinflammation
KW - Psilocybin
KW - Psychedelics
KW - suPAR
KW - TNF
U2 - 10.1016/j.cpnec.2022.100163
DO - 10.1016/j.cpnec.2022.100163
M3 - Journal article
C2 - 36545240
AN - SCOPUS:85143979977
VL - 13
JO - Comprehensive Psychoneuroendocrinology
JF - Comprehensive Psychoneuroendocrinology
SN - 2666-4976
M1 - 100163
ER -
ID: 363439711